JPS58222020A - Purgative for pretreatment - Google Patents

Abstract

PURPOSE:The titled purgative, containing picosulfate sodium in combination with magnesium citrate, easily administered, and capable of completely excreting and cleaning the contents in the colon in tests of the colon or abdominal surgical operation, etc. with almost no side effect. CONSTITUTION:A purgative for pretreatment containing (A) magneisum citrate and (B) picosulfate sodium: 4,4'-(2-pyridylmethylen)diphenolbis(sodium sulfate) monohydrate which is a laxative as active constituents. The dose thereof a time is 14-20g component (A) and 37-80mg component (B). Preferably the purgative is formulated in the form of a mixture (a solution). Thus, the dose of the magnesium citrate can be reduced, and side effects, e.g. nausea, vomiting or adbominal pain, are reduced to make the administration of the total dose possible. Thus, sufficient tests can be made.

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a laxative for pretreatment during colon examinations, abdominal surgery, and the like.

In recent years, a large percentage of patients have been diagnosed with colon cancer, for example, colon cancer.

Due to the increase in colon polyps, ulcerative colitis, colon clones, etc., the diagnosis of colon diseases is now required to be as detailed as the upper i.p. The importance of accurate diagnosis by X-ray contrast examination@- is increasing. In order to obtain an accurate test take in such a colon examination, it is necessary to perform a pretreatment that is appropriate for the examination and that places less of a burden on the patient. It is known that it has a great effect on the quality of fine structure visualization.Even during abdominal surgery, pretreatment to thoroughly remove intestinal contents is necessary.

Conventionally, for pretreatment for colon examinations and abdominal surgery,
A method of using laxatives such as Magnesium Citrate Solution 250- and Bisacodyl Tablets 9℃ Nnoside Tablets is often used, but the Magnesium Citrate Solution has an unpleasant taste and is in too large a quantity. There were problems such as side effects such as nausea, vomiting, and abdominal pain, as well as the inability to take full doses and not be able to perform adequate tests.

The inventors have proposed a pretreatment laxative 'fr which does not have the above-mentioned drawbacks.
As a result of intensive research for development, it was discovered that a combination of magnesium citrate and sodium picosulfate, a laxative, is a very preferred pretreatment laxative, and the present invention was achieved.

The present invention is a pretreatment laxative containing magnesium citrate and picofulfuride butrium as active ingredients.

The main component of the present invention is magnesium citrate. −
Human r7kin-1.2.3-pronoquinone tricarboxylic acid magnesium salt MgHC, H60) 5) 40 in 6
It is usually used as an aqueous liquid. Generally, what is called a magnesium citrate solution is an aqueous solution containing the above-mentioned magnesium citrate in an amount equivalent to 1.55 to 1.9 PK in terms of MgOVC.

This can be obtained, for example, by mixing and heating the following compositions.

For example, 250+n7! is a commercially available product. Madacolor (manufactured by Horii Pharmaceutical Co., Ltd.) containing 34% of magnesium citrate is known.

According to the present invention, the daily dose of magnesium citrate can be reduced by about 14 to 20 t (about 100 to 150 d as a liquid) from the conventional dose of about 309 d.

Sodium picosulfate (chemical name:
4,4'-(2-pyridyl-methylene) diphenol bis(sodium srunate) heptubide note) is
It is usually used in laxatives as water f#'llk7. As a commercially available product, for example, Laxoperone solution (manufactured by Teijin Pharmaceutical Co., Ltd.) containing 7.5 to 7.5 ml of sodium picosulfate per ml is known.

In the present invention, picosulfur-)-11-) I
) '11 um per dose is approximately 37 ~
80 (as a liquid, about 5 to 10) is appropriate, and it is preferable to use about 14 to 20 tons of the above-mentioned magnesium citrate and Nil as a liquid mixture (water solution).

The pretreatment laxative of the present invention consists of a small amount of tasteless and odorless sodium picosulfate and a smaller amount of magnesium citrate than conventional ones, and can be prepared as a liquid solution, so it is easy to take and has no side effects. During colon examinations, abdominal surgery, etc., the contents of the large intestine can be fully excreted and the large 115+ can be used as a purifier.

Hereinafter, the present invention will be explained in detail with reference to Examples.

Example 1 Preparation f for polypectomy of a colon polyp in a 38-year-old woman
The day before the test, I consumed one cup of ice cream (I P Ome) at 3pm as a low-residue diet using a modified Brown method.
) I gave them 11 servings of water, and from 5:00 to 6:00, I had them eat a dinner of fruitless soup, kudzu soup, juice, and 3-minute porridge.

At 7:30, I gave him another glass of water to drink. And 9
At half an hour, I added 125 ml of the pretreatment laxative of the present invention, namely a magnesium citrate solution (containing 17 ml of magnesium citrate) and 10 ηi of a sodium picosulfate aqueous solution (
Sodium picosulfate 75'II! ) were administered at the same time.

On the day of the test, drink a glass of water at 7am.

At 8 o'clock, I had a breakfast of coffee, tea, juice, etc. After that, I couldn't drink it until the end of the light analysis. AM 1.
At 0 o'clock, the intestine was examined using a fiberoptic colonoscope, and no fecal matter or mucous residue was observed in the rectum, sigmoid colon, descending colon, and 1st and 4th colon. A state of competence was ensured when the test was completed. ”
- A small amount of sticky residue was found in the colon and cecum, but it was aspirated.

It was easily cleaned by washing and the observation was satisfactory.

Example 2 A 20-year-old male patient with Crohn's disease was found to have stricture at the terminal ileum, but had soft bowel movements once a day regularly. For observation of lesions,
A fiberoptic colonoscope was used, and as a pretreatment, a low-residue diet according to Brown's modified method was provided on the day before the examination, as in Example 1, and thereafter, the same method as in Example 1 was used. Pretreatment laxative (125 ml of magnesium citrate solution + 1 ml of sodium picosulfate aqueous solution)
ad ), and the same conditions were used on the day of the test.
Then, when examining the patient, we observed the terminal 1i5I intestine as the bluest part to explore using a fiberoptic colonoscope (), and found that from the rectum, the sigmoid colon, descending colon, transverse colon, ascending colon, cecum, and terminal intestine. No stool or mucous residue was observed until the lesions appeared, allowing sufficient observation of the lesions.

Example 3 A 33-year-old male patient with Crohn's disease had ileocecal intestinal stenosis. In addition, his bowel movements continued to be diarrhea. A fiberoptic colonoscopy was performed to observe the lesions.As a pretreatment, the day before the examination, a low-residue diet of 1 c Brown was provided as in Example 1, and at 9:30 a.m. A pretreatment laxative (magnesium citrate solution 125-deca-sodium picosulfate aqueous solution 5-) was administered. Example 1 on the day of the test
At 10:00 a.m., we observed the terminal ileum using a fiberoptic colonoscope as the deepest part of the examination, and found that feces and mucus were found in the rectum, sigmoid colon, descending colon, 4% colon, ascending colon, and cecum. No residual material was observed, and the lesion could be sufficiently observed. A small amount of mucus-like residue was observed in the terminal ileum, but it was easily cleaned by suctioning and washing, making it possible to observe it.

Example 4 A 53-year-old female patient with irritable bowel syndrome had been complaining of diarrhea and constipation for the past 2 years, and no intestinal stricture was observed. On the day before the test, a low-residue diet using a modified Br0Wn diet was provided as in Example 1, and at 9:30 a. administered. On the day of the test, have at least one glass of water at 7am, coffee at 8am,
The subjects had tea, juice, etc. for breakfast, and were not allowed to eat or drink anything after this until the end of the test. Furthermore, 30 minutes before the examination, two Resicarbon suppositories were administered and the remaining side of the rectum was excreted, and then an X-ray contrast agent (67% W/V) 200- was used to remove the large intestine by enema. An X-ray examination was performed. The terminal ileum and cecum were the deepest parts of the examination, but the rectum, sigmoid colon, descending colon, transverse colon, ascending colon, cecum, terminal gyrus, and intestines were
There was no residual stool, the contrast agent applied well, and good images, including mesh images, were obtained.

Example 5 A 63-year-old woman had ascending colon cancer and had nearly complete intestinal stenosis at the site of resection. As a pretreatment for the colon enema test, the day before the test, perform the Brow procedure as in Example 1.
At 9 o'clock, the cows were fed with a pretreatment laxative of the present invention (citrate, magnesium solution 100%).
Ten picosulfate sodium aqueous solution 10d) was administered. Thereafter, in exactly the same manner as in Example 4, the large intestine
Conducted line inspection. In this patient, oral barium sulfate injection was not possible due to complete stenosis of the ascending colon.
Rectum, sigmoid colon.

There was no residual feces in the descending colon, tuberosity, and ascending colon, and we were able to obtain satisfactory images.

Claims (1)

[Claims] 1. A pretreatment laxative containing sodium picosulfate and magnesium citrate as active ingredients. Approximately 3 sodium picosulfate for 21 doses
7-80 +19 and magnesium citrate approximately 14-20
9. The laxative for pretreatment according to claim 1, characterized in that: a. The pretreatment laxative according to claim 1 or 2, which is in the form of a liquid solution.